Skip to main content
. 2022 Apr 27;81(8):1136–1142. doi: 10.1136/annrheumdis-2022-222212

Figure 7.

Figure 7

Relationship between baseline type I IFN signature and SRI-4 response rates at week 24 comparing placebo and iberdomide 0.45 mg treated SRI-4 cumulative response rates across the range of baseline type I IFN signature values (IFI27, IFI44, IFI44L and RSAD2). In exploratory analysis using bootstrapping and aggregating of thresholds from trees, the type I IFN signature optimal cut point was at 0.615 (interaction p=0.0037), SRI-4 at 0.45 mg=74% vs placebo=20%, OR=11.3 (2.9–43.8). this ‘IFN-Superhigh’ cut point captured 90/288 (31%) patients. At the extreme IFN >1.31 (top 14% of patients), in the iberdomide 0.45 mg group, 11/11 (100%) patients had an SRI-4 response. IFN, interferon; SLE, systemic lupus erythematosus; SRI-4, SLE Responder Index-4.